David Johnson

David Johnson brings more than 25 years of experience in the biopharmaceutical industry. His most recent executive position was with Acerta Pharma, an oncology-focused pharmaceutical company, where he was CEO and led the company through a critical phase of growth from approximately 40 to 150+ employees and from signal seeking first-in-human trials to more than 20 active clinical studies. His tenure included the launch of two global Phase 3 trials and culminated in the execution of a strategic transaction with AstraZeneca valued at up to $7 billion. Mr. Johnson’s prior experience spans from pre-clinical to all phases of clinical development. He has made meaningful contributions to drugs ultimately garnering NDA/SNDA approval including idelalisib, romidepsin, and bortezomib. He has held roles with increasing responsibilities within Clinical Development, Medical Affairs, Pipeline Development, and Commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche. Mr. Johnson is a proven leader, deeply-rooted in oncology with a long track record as a successful collaborator with a broad global network of investigators. He is a co-author on numerous publications including three NEJM publications. Mr. Johnson is a graduate of Indiana University.